GET DAILY SIGNALSAzitra (AZTR) Stock Declines -15% in 30 Days Following Reverse Split
Key Takeaways
- Azitra (AZTR) fell roughly 15% over the last 30 days, from an adjusted close near $0.72 in mid-October to about $0.61.
- The decline followed a 1-for-10 reverse stock split that took effect on October 26, 2026, cutting shares outstanding from approximately 60.6 million to 6.06 million.
- Third-quarter 2026 results showed a GAAP net loss of $0.29 per share, missing consensus estimates, with no revenue reported as the company remains pre-revenue.
- Maxim lowered its price target on Azitra to $4 from $10 while maintaining a Buy rating.
- Over the trailing three months, the stock is down roughly 56%, reflecting financing-related dilution and listing-compliance pressure.
- Positive pipeline updates, including the ATR-04 trial expansion and ATR-COSF data, have not yet offset concerns around the capital structure.
- For additional context, explore Azitra's Price Targets, Earnings, and Forecast pages.
- To discover curated, top-performing trading strategies, visit Trending AI Robots.
Azitra (AZTR) Company Overview and Market Position
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on precision dermatology. Based in Branford, Connecticut, the company develops engineered proteins and topical live biotherapeutic products designed to treat skin diseases. Its lead candidates include ATR-04, a genetically modified strain of S. epidermidis in a Phase 1/2 trial for rashes associated with EGFR inhibitor cancer therapy; ATR-12, in a Phase 1b/2a trial for Netherton syndrome; and ATR-01, in IND-enabling development for ichthyosis vulgaris. Azitra also maintains a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains. The company's discovery platform is built on a microbial library of roughly 1,500 bacterial strains augmented by artificial intelligence and machine learning. As a pre-revenue developer with a small employee base, Azitra is closely followed for its clinical data catalysts and financing strategy rather than current earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Azitra (AZTR) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AZTR declined approximately 15%. Using split-adjusted closing prices, the stock traded near $0.72 in mid-October before finishing near $0.61 in mid-November. The move was volatile, reflecting a sharp selloff into the reverse split, a brief post-split spike on unusually heavy volume, and subsequent downward pressure as earnings approached.
The quarterly trend is steeper. From a split-adjusted close near $1.39 in mid-August, the stock has fallen roughly 56% to its current level. The sustained decline reflects a combination of ongoing equity financing and dilution, a reverse stock split implemented to address exchange listing requirements, and limited offsetting clinical catalysts. The result is a small-cap name trading well below its 52-week high and near the lower end of its recent range.
What Drove AZTR Stock Price in the Last 30 Days
The dominant event was the 1-for-10 reverse stock split, announced in mid-October and effective October 26, 2026. The split reduced the share count from approximately 60.6 million to 6.06 million, a move aimed at lifting the share price to satisfy NYSE American minimum-bid listing standards. While a reverse split is mechanically neutral to market value, it is often read by investors as a sign of financial strain and is frequently followed by renewed selling pressure as holders and dilutive instruments adjust.
Third-quarter results, released in mid-November, added to the downside. The company reported a GAAP loss of $0.29 per share, missing consensus estimates by $0.04, with no revenue for the period. Around the same time, Maxim trimmed its price target to $4 from $10 while retaining a Buy rating, a revision that weighed on sentiment. These financial and rating developments overshadowed positive clinical news, including the expansion of the ATR-04 Phase 1/2 trial to include rashes associated with KRAS and MEK inhibitors and encouraging ex vivo ATR-COSF data on fine lines and elasticity. I reviewed the recent moves with Tickeron’s AI Pattern Search Engine to put the price action in context.
What Drove AZTR Stock Performance Over the Last Quarter
Across the trailing quarter, the broader narrative has been one of capital-structure pressure. Azitra has relied on a series of financings, including a private placement, an equity line of credit with Alumni Capital, and preferred-stock conversions, which have expanded the authorized share count and diluted existing holders. The company also continues to operate under a NYSE American deficiency notice related to stockholders' equity, with a plan to regain compliance by April 1, 2027.
Operationally, the company has advanced its pipeline despite the stock weakness. Management reported progress across ATR-04, ATR-12, and ATR-01, and introduced ATR-COSF as a new cosmetics and cosmeceuticals opportunity. These programs have not yet produced the clinical data or revenue needed to stabilize the equity, leaving the share price sensitive to financing activity and listing-status updates.
AZTR Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape AZTR over the coming months. First, management has indicated it anticipates initial first-in-human results for the ATR-COSF program by year-end, a milestone that could clarify the commercial potential of the cosmetics franchise. Progress on the ATR-04 Phase 1/2 trial and any updates on ATR-12 and ATR-01 will also be closely watched.
Financial and structural risks remain central. Investors will monitor cash runway and any additional use of the equity line of credit, which carries the potential for further dilution. The company's progress toward regaining NYSE American compliance by the April 2027 deadline is another key risk, as is the pace of warrant and preferred-stock conversions. Upcoming quarterly reports and any analyst rating or price-target changes will provide further signals on sentiment.
Using AI Tools for Market Context
In my own process, I find Tickeron’s AI Trading Bots helpful for reviewing algorithmic signals across a range of strategies and timeframes. The platform highlights top-performing bots on hundreds of tickers, allowing me to cross-check my fundamental views with quantitative outputs without replacing independent analysis. This approach adds another layer when evaluating names facing both clinical and structural pressures.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AZTR's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for AZTR moved out of overbought territory on October 27, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 instances where the indicator moved out of the overbought zone. In 9 of the 9 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AZTR as a result. In 54 of 56 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for AZTR turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 30 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
AZTR moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AZTR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +14.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTR advanced for three days, in 119 of 147 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
AZTR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. AZTR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.053) is normal, around the industry mean (3.498). P/E Ratio (36.625) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (146.534) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement